Lan Luo

1 month ago | tandfonline.com | Juliana Tay |Lan Luo |Zihui Zhou |Qing Zhang

ABSTRACTDespite the perceived benefits, the role of learner agency in interactive group discussions for active asynchronous learning remains relatively unexplored. This study aimed to address this research gap by employing a mixed-methods case study approach, analysing 256 forum posts and 37,599 rows of log data from the university’s virtual learning environment.

2 months ago | mdpi.com | Xinrui Wang |Jie Li |Jing Li |Lan Luo

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Dec 16, 2024 | peerj.com | Lan Luo

This review aimed at consolidating the current evidence about the efficacy and safety aspects of the two most common vascular closure devices (Angio-Seal and StarClose) by conducting a meta-analysis of aggregate data from a number of comparative studies. This was done to derive pooled effect estimates that would provide health service providers with stronger evidence about the performance of the respective devices in clinical settings.

Sep 16, 2024 | onlinelibrary.wiley.com | Xiaxia Chen |Wei Zhang |Lan Luo |Shimei Fu

1 INTRODUCTION More than 50% of patients are diagnosed with stage IV NSCLC,1-3 and the 5-year overall survival (OS) of NSCLC is still only 19%.4 IV NSCLC patients with EGFR gene-sensitive mutations, ALK gene or ROS1 gene fusion can be treated with first-line targeted drugs.5-8 Immunotherapy drugs such as pembrolizumab monoclonal antibodies can be used for patients with PD-L1 TPS ≥1%.9 Stage IV NSCLC patients without a driver gene is mainly treated by platinum-based systemic chemotherapy, and...

Apr 24, 2024 | mdpi.com | Lan Luo |Juan Shen |Bo Jin

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.